Kusajili – Centralise les essais cliniques mondiaux

Transcranial Direct Current Stimulation for Chronic Pain Relief In the present study, the investigators intend to investigate whether anodal transcranial direct current stimulation (tDCS) may be effective in reducing pain in chronic pain patients.

• Pays Aucun
• Organes Aucun
• Spécialités Aucun

Phase I/II Study of Celebrex and EPO906 in Patients With Metastatic Colorectal Cancer This study is for people with advanced colorectal cancer. This study uses the drugs Celebrex and EPO906. EPO906 is an experimental drug that has not been approved by the FDA. EPO906 is a drug that has been shown in the laboratory to cause cancer cells to die and prevents them from growing and reproducing. Celebrex is a drug that is approved by the FDA for the treatment of arthritis and prevention of colon polyps. Colon polyps are small growths in the colon. If not surgically removed, some colon polyps can become cancerous. Some studies have shown that Celebrex may reduce the side effects of chemotherapy. Other studies have shown that it may increase the effectiveness of some chemotherapy. Celebrex is not approved by the FDA for reducing the side effects of chemotherapy or improving the effectiveness of chemotherapy. The combination of EPO906 and Celebrex in this study is experimental. The main goal of this study is to see if adding the drug Celebrex to the drug EPO906 will decrease the amount of diarrhea seen in patients that receive EPO906. The goal of the first phase of this study is to find the highest dose of EPO906 that can be given safely with Celebrex. The dose of Celebrex will remain the same for the whole study. Higher doses of EPO906 will be given to each group of patients. The increase of EPO906 will stop once more than one patient has serious side effects. The highest dose of EPO906 that can be given with Celebrex (without serious side effects) will be called the pilot dose. The goal of the second phase of this study is to find out how tumors respond to these doses of the drugs. Another purpose of this study is to see how the body processes the EPO906 and Celebrex. This study will also look at the side effects of these drugs. In this study, we will measure how long subjects live, how often tumors shrink after receiving the study drugs, and how long it takes for tumors to increase in size after receiving the study drugs. This study will also measure the levels of genes, which are the cell's blueprint, in participant's tumors. Several genes can affect how people's bodies react to the cancer drugs. Genes will also be measured in participant's blood. We want to see if these predict response to the study drugs.

• Pays Aucun
• Organes Aucun
• Spécialités Aucun

EpSSG (European Soft Tissue Sarcoma Study Group) Protocol for Non-Metastatic Rhabdomyosarcoma in Children The purpose of the study is achieve standardization treatment of low and intermediate risk rhabdomyosarcoma patients, with an attempt to improve treatment results in high and very high risk patients by the addition of doxorubicin as induction treatment and at the maintenance phase.

• Pays Aucun
• Organes Aucun
• Spécialités Aucun

Salvage Use" of Recombinant Factor VIIa After Inadequate Haemostasis in Complex Cardiac Surgery Aims and Hypotheses: This randomised placebo controlled study will test the hypothesis that Recombinant Activated Factor VII (rVIIa) will improve haemostasis after an inadequate response to conventional therapy in complex cardiac surgery. Major bleeding is still of concern in complex cardiac surgery. It has been shown to be associated with poorer patient outcome and results in the consumption of resources (hospital costs, manpower and blood bank reserves). This study has the potential to provide evidence that rVIIa can reduce transfusion requirements and improve patient outcome in a problematic aspect of complicated cardiac surgery. The objective is to conduct a multi-centre randomised placebo controlled study that has been designed to scientifically evaluate the treatment of post bypass coagulopathy in the association with complex cardiac surgery. The trial design is based on clinical practice that has evolved over 2 years at the Austin Hospital during which 38 patients have received open label administration of rVIIa. There is currently no published RCT in this area and there is no TGA approval for the use of rVIIa for this indication.

• Pays Aucun
• Organes Aucun
• Spécialités Aucun

Imatinib Mesylate and Cytarabine in Treating Patients With Newly Diagnosed Chronic Myeloid Leukemia RATIONALE: Imatinib mesylate may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining imatinib mesylate and chemotherapy may kill more cancer cells. PURPOSE: Phase I/II trial to study the effectiveness of imatinib mesylate plus cytarabine in treating patients who have newly diagnosed chronic myeloid leukemia.

• Pays Aucun
• Organes Aucun
• Spécialités Aucun

Tranexamic Acid in Dacryocystorhinostomy Single dose tranexamic acid (TA) before dacryocystorhinostomy (DCR) operation: a prospective, double blind, placebo controlled study. The study hypothesis: TA in DCR might reduce the intraoperative and postoperative bleeding in DCR surgery, and might reduce the duration of the surgery.

• Pays Aucun
• Organes Aucun
• Spécialités Aucun

Assessing Different Methods of Anxiety Care in Pediatric Settings This study will compare the effectiveness of delivering cognitive behavioral therapy for children with anxiety disorders through in-person contact versus through workbooks and telephone communication.

• Pays Aucun
• Organes Aucun
• Spécialités Aucun

Transfusion Alternatives Pre-Operatively in Sickle Cell Disease (TAPS) TAPS is a sequential trial which aims to investigate whether the administration of a blood transfusion pre-operatively to patients with sickle cell disease (HB SS or Hb SB0 thal)having low or medium risk elective surgery increases or decreases the overall rate of peri-operative complications. The proportion of patients with peri-operative complications in two randomised groups of transfused and untransfused patients will be compared.

• Pays Aucun
• Organes Aucun
• Spécialités Aucun

Influence of the Psychophysiological Status of Elite Judo Athletes on Their Performance and Injury Judo is one of the possible items in our country to win the first prize in Olympics. However, scientific research in this field is not enough to support the coaches to train the athletes. Series of research should be planned and executed to help the coaches and to promote the performance of our athletes. This is the first step of the serial research. The purposes of this study are: in the first year, to find the correlations between the physiological/psychological competitive abilities of the second/third year athletes and their performance/injury status. And, the physiological/ psychological competitive abilities of the first year athletes will be collected in the beginning of this year. And then, their performance/injury status will be followed through the whole year and to the end of the second year monthly. The purposes of this study in the second year are to find the causation of the physiological/ psychological competitive abilities in the first year with the performance/injury status in the second year. The subjects of this study are from 4 senior high schools in the north part of Taiwan which performed well in national judo competition in senior high schools in the past years. The study designs are both cross-sectional and prospective. In the part of the second/third year athletes, it is a cross-sectional design, and in the part of the first year athletes, it is a prospective design. The physiological status will be assessed with their general fitness and balance. The fitness test includes body composition, strength, power, endurance, agility, coordination, balance, flexibility, and cardiopulmonary capacity. The psychological competitive abilities will be assessed with a questionnaire. Injury and the possible causes will also be collected with a questionnaire monthly. Finally, the data will be analyzed with descriptive analysis, chi-square test, t-test and regression analysis to show their characteristics, correlations and causations.

• Pays Aucun
• Organes Aucun
• Spécialités Aucun

Guanfacine Adjunctive Treatment to Atypical Antipsychotics for Cognitive Dysfunction in Schizophrenia Our overall aim is to determine if the administration of guanfacine in combination with aripiprazole, olanzapine, quetiapine, and/or risperidone is significantly more effective than any of those medications alone in treating some of the cognitive impairment in schizophrenia.

• Pays United States,
• Organes Aucun
• Spécialités Aucun